RECOVER: A Randomized Open-label Phase-II Trial with or without Infusion of Convalescent Plasma in High-Risk Patients with Severe COVID-19 Disease

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:2 publications

Grant number: 01KI20152

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $2,402,898.3
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

    Pending
  • Research Location

    Germany, Europe
  • Lead Research Institution

    Universitätsklinikum Heidelberg
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Older adults (65 and older)

  • Vulnerable Population

    Individuals with multimorbidityOther

  • Occupations of Interest

    Unspecified

Abstract

clinical trial - Convalescent plasma (CP) has been hypothesized to improve outcome in COVID-19 patients. Randomized trials are urgently needed for high-risk patients especially prior to full blown ARDS and mechanical ventilation. This multicenter phase II trial will analyze the effects of CP in high-risk patients with COVID-19 infection. Patients at high risk for a poor outcome due to underlying disease (group 1, pre-existing or concurrent hematological malignancy and/or ongoing chemotherapy for cancer; group 2, chronic immunosuppression not meeting criteria group 1; group 3, age 50-75 years and lymphopenia <0>1µg/mL not meeting criteria groups 1 or 2; group 4, age = 75 years not meeting criteria for either 1, 2 or 3) are eligible for enrollment. Eligibility also requires PCR confirmed SARS-CoV-2 infection and O2 saturation =93% while breathing ambient air. Patients are randomized to receive (experimental arm) or not receive (standard arm) convalescent plasma from two different donors (day1, day2). A cross-over from the standard arm into the experimental arm is possible after day 10 in case of not improving or worsening clinical condition. The primary endpoint is the time to clinical improvement defined as two points improvement on a seven-point ordinal scale of patient state of health or discharge alive from the hospital. Secondary outcomes are mortality, changes in clinical scores, inflammatory cytokine changes and viral load dynamics. This trial systematically assesses the therapeutic role of convalescent plasma for treating SARS-CoV-2 infection in a high-risk patient population.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation.

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.